Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form. (UniProt)
Formulation
Antibody in PBS with 0.02% sodium azide and 50% glycerol
Host
Rabbit
Immunogen Region
A synthetic peptide specific to human PF4 was used as the immunogen for the PF4 antibody.